晚期卵巢癌新辅助化疗的临床结局
回顾性研究纳入2003—2015年连续诊治的263例晚期(III–IV期)卵巢癌患者,其中127例接受新辅助化疗(NACT),136例接受初次肿瘤细胞减灭术(PDS)后辅助化疗。IIIc期患者中PDS组总生存(OS)长于NACT组(中位OS 60.2 vs 48.8个月,P=0.039);NACT组完全细胞减灭率高于PDS组(65.9% vs 40.2%,P=0.001)。作者结论认为PDS与结局改善相关,NACT可能改善PDS后仍有残留病灶患者的生存。
要点
- IIIc期卵巢癌中PDS组中位OS 60.2个月,长于NACT组的48.8个月(P=0.039)。
- NACT组完全细胞减灭率65.9%,高于PDS组的40.2%(P=0.001)。
- PDS后达完全细胞减灭者中位OS 106个月,为各组最佳。
核心结论
- PDS与结局改善相关。
- NACT似乎可改善那些在PDS后仍会有残留病灶、并在间歇性细胞减灭术时达到完全细胞减灭的患者的生存结局。
- 对于不适合在PDS时达到完全细胞减灭的选定患者,可采用这一治疗选择。
研究设计与样本
- 回顾性研究,纳入2003—2015年间连续诊断并治疗的晚期(III–IV期)卵巢癌患者,共263例,其中127例接受NACT,136例接受PDS后辅助化疗。
主要发现
- IIIc期患者中PDS组中位OS为60.2个月,NACT组为48.8个月(P=0.039)。
- NACT组完全细胞减灭率为65.9%,PDS组为40.2%(P=0.001)。
- PDS后达完全细胞减灭者中位OS 106个月,NACT后达完全细胞减灭者中位OS 71个月,PDS后有残留病灶者中位OS 55个月。
- NACT后间歇性细胞减灭术仍有残留病灶者中位OS 36个月,为最差结局。
- 一线及二线化疗后的铂类敏感性与是否接受NACT相似。
临床怎么用
- 作者认为,对于不适合在PDS时达到完全细胞减灭的选定患者,可采用NACT这一治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate clinical outcome in patients selected to receive neoadjuvant chemotherapy (NACT) compared to primary debulking surgery (PDS). METHODS: Retrospective study including all consecutive patients diagnosed and treated for advanced (stages III-IV) ovarian cancers between the years 2003-2015. RESULTS: 263 women were included in the study, of these, 127 patients were selected to receive NACT and 136 were treated with PDS followed by adjuvant chemotherapy. PDS was associated with longer OS in stage IIIc disease (median OS: 60.2 vs. 48.8months; p-value 0.039) compared with NACT. Patients achieved higher rates of complete cytoreduction in the NACT group compared to the PDS group (65.9% vs. 40.2%; p=0.001). Patients attaining complete cytoreduction after PDS had the best survival, (median OS 106months) followed by those with complete cytoreduction after NACT (median OS 71months), followed by those with residual disease after PDS (median OS 55months). Patients with residual disease following interval debulking after NACT had the worst outcome (median OS 36months). Platinum sensitivity following first line and second line chemotherapy was similar whether patients received neoadjuvant chemotherapy or not. CONCLUSION: PDS was associated with improved outcome. NACT appears to improve survival outcome in patients that would have had residual disease after PDS, and attain complete cytoreduction at the time of interval cytoreduction. This treatment option can be used in selected patients that are not candidates for complete cytoreduction at PDS.
引用
- Kessous R, Laskov I, Abitbol J, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2016. PMID: 28041690. doi:10.1016/j.ygyno.2016.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。